Galapagos NV Stock News

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday

\-- Companies to jointly validate novel drug targets -- \-- Scipher eligible for upfront, opt-in and milestone payments -- \-- Galapagos to progress selected targets into drug discovery -- Mechelen,

* First half-year 2020 financial results: * Group revenues and other income of €224.6 million * Operating loss of €130.8 million * Net loss of €165.6 million * Cash and current finan

GILD sank back into its familiar pattern of disappointing the Street, selling off below $70 again after reporting Q2 results.

\-- Clinical Development Program of Filgotinib Demonstrated Durable Efficacy Balanced with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks -- Foster City, Calif., and Mechelen, B

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) announced today the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted

Stocks to consider as biotech company Novavax gets $1.6 billion in federal aid for Covie-19 vaccine Continue reading...

Is an industry leader in treating cystic fibrosis or a company with a potential miracle drug the better buy for investors?

In this article we will take a look at whether hedge funds think Galapagos NV (NASDAQ:GLPG) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into h

(Bloomberg Opinion) -- There are good reasons for Britain’s AstraZeneca Plc to consider what would be the biggest pharmaceuticals deal in history by combining with U.S. peer Gilead Sciences Inc. Th

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced new analyses from two clinical trials evaluating filgotinib, an investigational, oral, selective JAK1 in

European stocks moved off their lowest levels of the day on a slightly more aggressive European Central Bank move than expected.

Galapagos rose nearly 3% in early Amsterdam trade as Phase 3 studies of drug it's making with Gilead Sciences showed "sustained efficacy and a consistent safety profile" in treating moderately to se

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced Week 52 results from the Phase 3 FINCH 1 and FINCH 3 studies of filgotinib, an investigational, oral, se

In a phase 2b/3 study in ulcerative colitis, the drug candidate met its goals, but with results that didn't appear better than those of a potential competitor.